ADR AC GmbH ^Company

ADR-AC has longtime expertise in drug hypersensitivity research. In case of adverse drug reactions during pre-clinical stages, phase I - III clinical trials or in post-marketing stages, ADR-AC offers defined risk assessment to analyze and evaluate the immune-stimulatory potential of culprit substances. Our know-how in the field of small chemicalmolecules as well as biologicals, eg therapeutic proteins and monoclonal antibodies.